Literature DB >> 21619483

Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.

Petr Ricanek1, Stephan Brackmann, Gøri Perminow, Lars G Lyckander, Jon Sponheim, Oyvind Holme, Ole Høie, Andreas Rydning, Morten H Vatn.   

Abstract

OBJECTIVE: The present population based adult cohort was part of a new prospective study of patients with inflammatory bowel disease (IBD) in South-Eastern Norway, the Inflammatory Bowel South-Eastern Norway II study, investigating disease characteristics in an attempt to improve our knowledge regarding factors related to early clinical phenotype and disease activity.
MATERIAL AND METHODS: Patients suspected to have IBD on the basis of predefined symptoms, including abdominal pain, diarrhea, and/or blood in stool for more than 10 days were examined at the local hospital. Colonoscopy with biopsies was performed and blood and stool samples were taken.
RESULTS: In ulcerative colitis (UC) patients, the median Simple Clinical Colitis Activity Index (SCCAI) was 4 (range 0-10) in mild and 6 (range 0-14) in patients with moderate or severe endoscopic activity of inflammation (p = 0.002). The calprotectin concentration in feces was significantly related to the SCCAI (p = 0.034) and the Mayo endoscopic subscore (p = 0.031). There was a significant association between the C-reactive protein (CRP) value, leucocytes and thrombocytes and the SCCAI, but only leucocytes were significantly associated with the Mayo endoscopic subscore. In Crohn's disease (CD) patients, there was no statistical significant association between the Harvey-Bradshaw Index (HBI) and the endoscopic grade of mucosal inflammation (p = 0.8). The calprotectin concentration in feces was significantly related to the endoscopic activity score (p = 0.004), but not to the HBI (p = 0.5). HBI was significantly related to the CRP value (p = 0.047) and thrombocytes (p = 0.03).
CONCLUSIONS: In UC, both biochemical and fecal markers are related to disease activity and extent of disease, whereas in CD, the fecal calprotectin concentration is a reliable marker of mucosal affection, but not for systemic disease activity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21619483     DOI: 10.3109/00365521.2011.584897

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  42 in total

Review 1.  Fibrogenesis and fibrosis in inflammatory bowel diseases: Good and bad side of same coin?

Authors:  Mariabeatrice Principi; Floriana Giorgio; Giuseppe Losurdo; Viviana Neve; Antonella Contaldo; Alfredo Di Leo; Enzo Ierardi
Journal:  World J Gastrointest Pathophysiol       Date:  2013-11-15

2.  Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis.

Authors:  Emanuel Burri; Christoph Beglinger; Stefanie von Felten; Frank Serge Lehmann
Journal:  Dig Dis Sci       Date:  2014-10-26       Impact factor: 3.199

Review 3.  The role and utility of faecal markers in inflammatory bowel disease.

Authors:  Frank S Lehmann; Emanuel Burri; Christoph Beglinger
Journal:  Therap Adv Gastroenterol       Date:  2015-01       Impact factor: 4.409

4.  Utility of faecal calprotectin analysis in adult inflammatory bowel disease.

Authors:  Lyn A Smith; Daniel R Gaya
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

5.  How useful are blood and stool biomarkers for detecting subclinical mucosal inflammation in ulcerative colitis?

Authors:  Byong Duk Ye
Journal:  Dig Dis Sci       Date:  2014-01-17       Impact factor: 3.199

6.  [Diagnostic options. Indications and validity].

Authors:  A Stallmach; M Bürger; M Weber
Journal:  Internist (Berl)       Date:  2014-08       Impact factor: 0.743

7.  Circadian Rhythm Disruption Aggravates DSS-Induced Colitis in Mice with Fecal Calprotectin as a Marker of Colitis Severity.

Authors:  Joseph Amara; Youakim Saliba; Joelle Hajal; Viviane Smayra; Jules-Joel Bakhos; Raymond Sayegh; Nassim Fares
Journal:  Dig Dis Sci       Date:  2019-05-21       Impact factor: 3.199

8.  Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.

Authors:  Anna-Maija Puolanne; Kaija-Leena Kolho; Henrik Alfthan; Ari Ristimäki; Harri Mustonen; Martti Färkkilä
Journal:  Dig Dis Sci       Date:  2017-09-25       Impact factor: 3.199

9.  Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma.

Authors:  Frank Serge Lehmann; Francesca Trapani; Ida Fueglistaler; Luigi Maria Terracciano; Markus von Flüe; Gieri Cathomas; Andreas Zettl; Pascal Benkert; Daniel Oertli; Christoph Beglinger
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

10.  Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis.

Authors:  Didia Bismara Cury; Sender Jankiel Mizsputen; Clara Versolato; Luciana Odashiro Miiji; Edson Pereira; Maria Aparecida Delboni; Nestor Schor; Alan C Moss
Journal:  Cell Immunol       Date:  2013-04-23       Impact factor: 4.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.